Franklin Resources Inc Prometheus Biosciences, Inc. Transaction History

Franklin Resources Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$103.46 - $126.29 $19.5 Million - $23.7 Million	-188,038 Reduced 40.71%	273,810 $29.4 Million
Q4 2022 Feb 10, 2023	SELL	$36.06 - $117.21 $2.41 Million - $7.83 Million	-66,789 Reduced 12.63%	461,848 $50.8 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $1,859 - $3,894	66 Added 0.01%	528,637 $31.2 Million
Q2 2022 Aug 11, 2022	BUY	$22.39 - $38.94 $3,851 - $6,697	172 Added 0.03%	528,571 $14.9 Million
Q1 2022 May 13, 2022	SELL	$30.13 - $50.0 $864,761 - $1.44 Million	-28,701 Reduced 5.15%	528,399 $20 Million
Q2 2021 Aug 13, 2021	SELL	$16.8 - $29.65 $885,427 - $1.56 Million	-52,704 Reduced 8.64%	557,100 $13.7 Million
Q1 2021 May 13, 2021	BUY	$16.51 - $25.29 $10.1 Million - $15.4 Million	609,804 New	609,804 $11.1 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.